Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
EXACT Sciences Corporation
EXACT Sciences Reports on LabCorp's Plans to Launch a New Laboratory-developed Stool-based DNA Screening Test for Colorectal Cancer in 2008
June 17th, 2008
EXACT Sciences Corporation (NASDAQ: EXAS) announced that Laboratory Corporation of America(R) Holdings (LabCorp(R)) informed EXACT that it plans to launch a single-marker, laboratory-developed, stool-based DNA test for colorectal cancer screening in 2008. In connection with the planned transition to the new test, LabCorp has stopped offering PreGen-Plus(TM), the version of the stool-based DNA technology that has been the subject of Food and Drug Administration (FDA) inquiry over the past several years. Instead, LabCorp plans to move to a new stool-based DNA test, which is different from EXACT's Version 2 technology and is based solely on the Vimentin gene, a methylated DNA marker that in...
Source: Cancer Weekly (2008-06-17)
|
